Adacel Tdap (diphtheria,pertussis(acellular),tetanus vaccine/PF)

The dosing schedule (i.e., number of doses) and specific preparation for primary and/or booster immunization (i.e., DTaP, Tdap) varies depending on age. The age-appropriate recommendations for the specific preparation used should be followed.

If licensed and indicated for a patient's age, combination vaccines may be used interchangeably with monovalent formulations and other combination products with similar component antigens produced by the same manufacturer to continue a vaccine series. Combination vaccines are not necessarily interchangeable with other combination vaccines from different manufacturers. ACIP prefers that vaccine doses in a series come from the same manufacturer; however, if this is not possible or if the manufacturer of prior doses is not known, it is recommended to administer the vaccine that is available.

DTaP (Daptacel(R), Infanrix(R)) is used only in infants and children 6 weeks through 6 years of age.

Tdap (Adacel(R), Boostrix(R)) is used in patients >=10 years of age; Adacel(R) is approved for use in patients up to 64 years of age.

The usual dose of DTaP or Tdap is 0.5 mL.

Diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed (DTaP) and tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed (Tdap) are administered only by IM injection. DTaP and Tdap should not be administered subcutaneously, intradermally, or IV.

Diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed (DTaP) is also available in fixed-combination vaccines containing DTaP and poliovirus antigens (DTaP-IPV; Kinrix(R), Quadracel(R)); DTaP, hepatitis B (HepB), and poliovirus antigens (DTaP-HepB-IPV; Pediarix(R)); DTaP, poliovirus, and Haemophilus influenzae type b (Hib) antigens (DTaP-IPV/Hib; Pentacel(R)); and DTaP, HepB, poliovirus, and Hib antigens (DTaP-HepB-IPV/Hib; Vaxelis(R)). Consult the prescribing information for these fixed-combination vaccines for additional information.

To ensure delivery into muscle, IM injections should be made at a 90degrees angle to the skin using a needle length appropriate for the individual's age and body mass, thickness of adipose tissue and muscle at the injection site, volume to be administered, and injection technique.

Depending on patient age, IM injections of DTaP or Tdap should be made into the anterolateral muscles of the thigh or deltoid muscle of the arm. In adults, adolescents, and children 3 years of age or older, IM injections should preferably be made in the region of the deltoid muscle. In infants and children 6 weeks through 1 year of age, IM injections should preferably be made into the anterolateral thigh; alternatively, the deltoid muscle can be used in those 1 through 2 years of age if muscle mass is adequate.

DTaP and Tdap should not be injected into the gluteal area or any area where there may be a major nerve trunk. If the gluteal muscle is chosen for infants <12 months of age because of special circumstances (e.g., physical obstruction of other sites), it is essential that the clinician identify anatomic landmarks prior to injection.

DTaP and Tdap should be inspected visually for particulate matter and discoloration prior to administration. Prior to use, vials or prefilled syringes of DTaP or Tdap should be shaken vigorously until a uniform, turbid, white suspension results. DTaP and Tdap should not be used if the vaccines cannot be resuspended.

DTaP or Tdap should not be mixed with any other vaccine or solution. Although DTaP is commercially available in a kit containing DTaP and inactivated poliovirus vaccine (DTaP-IPV) and Hib vaccine to provide a combination vaccine containing DTaP, poliovirus, and Hib antigens (DTaP-IPV/Hib; Pentacel(R)), extemporaneous vaccine combinations of DTaP or Tdap and other commercially available vaccines should not be prepared by admixing the vaccines.

Use of fixed-combination vaccines can reduce the number of injections a patient receives and alleviate concerns about the number of injections. When multiple vaccines are administered during a single health-care visit, each parenteral vaccine should be given with a different syringe and at different injection sites. Injection sites should be separated by at least 1 inch (if anatomically feasible) to allow appropriate attribution of any local adverse effects that may occur. For infants and children receiving >2 vaccines in a single limb, the thigh is the preferred site due to greater mass. For older children and adults, more than one IM injection can be administered into the deltoid muscle.

DTaP (Daptacel(R) , Infanrix(R) ) and Tdap (Adacel(R) , Boostrix(R) ) should be stored at 2-8degreesC and should not be frozen. Any DTaP or Tdap vaccine that has been frozen should be discarded.

No dosing information is available for this tab.

There is no enhanced messaging for this drug.

Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient.

Non-Live Or Non-Replicating Vaccines/Efalizumab

SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient.

MECHANISM OF ACTION: Efalizumab-induced immunosuppression may prevent proper immune response to the vaccine.(1)

CLINICAL EFFECTS: The use of vaccines in patients who have recently received efalizumab may be ineffective.(1)

PREDISPOSING FACTORS: None determined.

PATIENT MANAGEMENT: Patients should receive all appropriate immunizations prior to beginning efalizumab therapy. The use of vaccines in patients who have recently received efalizumab may be ineffective.(1) Patients who are vaccinated within the 14 days prior to initiating immunosuppressive therapy should be considered unvaccinated and should be revaccinated at least 3 months after immunosuppressive therapy is discontinued when immune competence is restored.(2)

DISCUSSION: In a small study with intravenous efalizumab, a single dose of 0.3 mg/kg of efalizumab given before primary immunization with a neoantigen decreased the secondary immune response, and a dose of 1 mg/kg almost completely ablated it. (This dose has comparable pharmacodynamic effects to the recommended subcutaneous dose of 1 mg/kg.) In chimpanzees treated with greater than 10 times the normal clinical exposure level of efalizumab, antibody responses were decreased following immunization with tetanus toxoid compared with untreated control animals.(1)

Non-Live, Non-Replicating Vaccine/Rebisufligene Etisparvovec

SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient.

MECHANISM OF ACTION: Rebisufligene etisparvovec therapy may decrease the effectiveness of vaccines. The mechanism is not known.(1)

CLINICAL EFFECTS: The expected serum antibody response may not be obtained.(1)

PREDISPOSING FACTORS: None determined.

PATIENT MANAGEMENT: The US manufacturer of rebisufligene etisparvovec states that vaccines should be avoided 30 days prior to rebisufligene etisparvovec administration.(1)

DISCUSSION: Rebisufligene etisparvovec therapy may decrease the effectiveness of vaccines.(1)

Vaccines/Pariglasgene Brecaparvovec

SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient.

MECHANISM OF ACTION: Pariglasgene brecaparvovec therapy may decrease the effectiveness of vaccines. The mechanism is not known.(1)

CLINICAL EFFECTS: The expected serum antibody response may not be obtained.(1)

PREDISPOSING FACTORS: None determined.

PATIENT MANAGEMENT: The US manufacturer of pariglasgene brecaparvovec states that vaccines should be avoided for 1 month prior to pariglasgene brecaparvovec administration.(1)

DISCUSSION: Pariglasgene brecaparvovec therapy may decrease the effectiveness of vaccines.(1)

Severe Interaction: Action is required to reduce the risk of severe adverse interaction.

Non-Live Or Non-Replicating Vaccines/Teplizumab

SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction.

MECHANISM OF ACTION: Teplizumab may cause lymphopenia and alter the immune system's response to vaccines.(1)

CLINICAL EFFECTS: Administration of a non-live vaccine within the 2 weeks prior to, during, or for 6 weeks following teplizumab therapy may result in decreased effectiveness of the vaccine.(1)

PREDISPOSING FACTORS: None determined.

PATIENT MANAGEMENT: Ideally, administer vaccines prior to initiating teplizumab therapy. The manufacturer of teplizumab states that non-live vaccines (e.g., inactivated or mRNA vaccines) are not recommended within the 2 weeks prior to, during, or for 6 weeks after stopping teplizumab therapy.(1) The immune response to non-live vaccines should be monitored in patients who receive teplizumab within these time frames. The Centers for Disease Control's (CDC) Advisory Committee on Immunization Practices (ACIP) states that non-live vaccines should be used with caution in patients who are severely immunosuppressed. Patients who are vaccinated within the 14 days prior to initiating immunosuppressive therapy should be considered unvaccinated and should be revaccinated at least 3 months after immunosuppressive therapy is discontinued when immune competence is restored.(2) For COVID-19 vaccines, the CDC advises planning for vaccination at least 2 weeks before starting or resuming immunosuppressive therapy. Patients should be offered and given a COVID-19 vaccine even if the use and timing of immunosuppressive agents cannot be adjusted. The CDC states that an age-appropriate mRNA COVID-19 vaccine is preferred over the Janssen COVID-19 vaccine for the primary and booster doses for immunocompromised patients. All immunocompromised patients over 5 years of age should receive at least 1 booster dose if eligible. See the CDC's Interim Clinical Considerations for Use of COVID-19 Vaccines for age- and product-specific recommendations.(3)

DISCUSSION: Vaccinations may be less effective if administered within 2 weeks before, during, and for 6 weeks following teplizumab therapy.(1)

Moderate Interaction: Assess the risk to the patient and take action as needed.

Non-Live Or Non-Rep Vaccines/Systemic Corticosteroids; Acth

SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed.

MECHANISM OF ACTION: Corticosteroids and corticotropin suppress the immune system and may alter the immune system's response to vaccines.(1)

CLINICAL EFFECTS: Vaccines administered during or within 2 weeks prior to therapy with corticosteroids or corticotropin may result in decreased effectiveness of the vaccine.(1)

PREDISPOSING FACTORS: Patients receiving immunosuppressive doses of corticosteroids or corticotropin for equal to or greater than 14 consecutive days.(1)

PATIENT MANAGEMENT: The Centers for Disease Control's (CDC) Advisory Committee on Immunization Practices (ACIP) states that non-live vaccines should be used with caution in patients who are severely immunosuppressed, including those who are receiving or have received high-dose, systemic steroids for greater than or equal to 14 consecutive days. When initiating immunosuppressives doses of corticosteroids, wait 2 weeks after a non-live vaccines is administered. However, if patients require therapy for chronic inflammatory conditions, do not delay therapy due to past vaccines.(1) The immune response to non-live vaccines should be monitored in patients receiving corticosteroids. Vaccinations given during corticosteroid therapy may need to be repeated.(1) Patients who are vaccinated within the 14 days prior to initiating immunosuppressive therapy should be considered unvaccinated and should be revaccinated at least 3 months after immunosuppressive therapy is discontinued when immune competence is restored.(1)

DISCUSSION: Vaccinations given during and within 2 weeks prior to corticosteroid therapy may be less effective. However they are considered safe to administer.(1) Many clinicians consider a dose equivalent to either 2 mg/kg of body weight or a total of 20 mg/day of prednisone as sufficiently immunosuppressive to raise safety concerns about live-virus vaccines.(1) Immunization procedures may be undertaken in patients receiving corticosteroids when the therapy is short term (less than 2 weeks); low to moderate dose; long-term, alternate-day treatment with short-acting preparations; maintenance physiologic doses (replacement therapy); or administered topically (skin or eyes), by aerosol, or by intra-articular, bursal, or tendon injection.(1)

Non-Live Or Non-Replicating Vaccines/Etrasimod

SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed.

MECHANISM OF ACTION: Etrasimod is an immunosuppressant and may alter the immune system's response to vaccines.(1)

CLINICAL EFFECTS: Administration of a vaccine during and for up to 5 weeks after discontinuation of etrasimod therapy may result in decreased effectiveness of the vaccine. Etrasimod treatment should be paused 5 weeks prior and for 4 weeks after vaccination.(1)

PREDISPOSING FACTORS: None determined.

PATIENT MANAGEMENT: Ideally, administer vaccines prior to initiating etrasimod therapy. The immune response to non-live vaccines should be monitored in patients receiving etrasimod or who have received etrasimod in the previous 5 weeks. Vaccinations given during and for up to 5 weeks after discontinuation of etrasimod therapy may need to be repeated.(1) The Centers for Disease Control's (CDC) Advisory Committee on Immunization Practices (ACIP) states that non-live vaccines should be used with caution in patients who are severely immunosuppressed. Patients who are vaccinated within the 14 days prior to initiating immunosuppressive therapy should be considered unvaccinated and should be revaccinated at least 3 months after immunosuppressive therapy is discontinued when immune competence is restored.(2)

DISCUSSION: Vaccinations may be less effective if administered during and for up to 5 weeks after etrasimod treatment.(1) However they are considered safe to administer.

Non-Live Or Non-Replicating Vaccines/Fingolimod

SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed.

MECHANISM OF ACTION: Fingolimod is an immunosuppressant and may alter the immune system's response to vaccines.(1)

CLINICAL EFFECTS: Administration of a vaccine during and for 2 months following fingolimod therapy may result in decreased effectiveness of the vaccine.(1,2)

PREDISPOSING FACTORS: None determined.

PATIENT MANAGEMENT: Ideally, administer vaccines prior to initiating fingolimod therapy. The immune response to non-live vaccines should be monitored in patients receiving fingolimod or who have received fingolimod in the previous two months. Vaccinations given during and for 2 months after stopping fingolimod therapy may need to be repeated.(1,2) The Centers for Disease Control's (CDC) Advisory Committee on Immunization Practices (ACIP) states that non-live vaccines should be used with caution in patients who are severely immunosuppressed. Patients who are vaccinated within the 14 days prior to initiating immunosuppressive therapy should be considered unvaccinated and should be revaccinated at least 3 months after immunosuppressive therapy is discontinued when immune competence is restored.(3)

DISCUSSION: Vaccinations may be less effective during and for 2 months following fingolimod therapy(1) however they are considered safe to administer.(2)

Non-Live Or Non-Replicating Vaccines/Ocrelizumab

SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed.

MECHANISM OF ACTION: Ocrelizumab is an immunosuppressant and may alter the immune system's response to vaccines.(1)

CLINICAL EFFECTS: Administration of a non-live vaccine within 2 weeks before or during ocrelizumab therapy may result in decreased effectiveness of the vaccine. If possible, non-live vaccines should be administered at least two weeks prior to initiating ocrelizumab therapy.(1)

PREDISPOSING FACTORS: None determined.

PATIENT MANAGEMENT: Ideally, administer non-live vaccines at least two weeks prior to initiating ocrelizumab therapy. The immune response to non-live vaccines should be monitored in patients receiving ocrelizumab. Vaccinations given during ocrelizumab therapy may need to be repeated.(1) Patients who are vaccinated within the 14 days prior to initiating immunosuppressive therapy should be considered unvaccinated and should be revaccinated at least 3 months after immunosuppressive therapy is discontinued when immune competence is restored.(2)

DISCUSSION: Vaccinations may be less effective if administered within 2 weeks before or during ocrelizumab treatment.(1)

Non-Live Or Non-Replicating Vaccines/Ozanimod

SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed.

MECHANISM OF ACTION: Ozanimod is an immunosuppressant and may alter the immune system's response to vaccines.(1)

CLINICAL EFFECTS: Administration of a vaccine during and for up to 3 months after discontinuation of ozanimod therapy may result in decreased effectiveness of the vaccine. Ozanimod treatment should be paused 3 months prior and for 1 month after vaccination.(1)

PREDISPOSING FACTORS: None determined.

PATIENT MANAGEMENT: Ideally, administer vaccines prior to initiating ozanimod therapy. The immune response to non-live vaccines should be monitored in patients receiving ozanimod or who have received ozanimod in the previous 3 months. Vaccinations given during and for up to 3 months after discontinuation of ozanimod therapy may need to be repeated.(1) The Centers for Disease Control's (CDC) Advisory Committee on Immunization Practices (ACIP) states that non-live vaccines should be used with caution in patients who are severely immunosuppressed. Patients who are vaccinated within the 14 days prior to initiating immunosuppressive therapy should be considered unvaccinated and should be revaccinated at least 3 months after immunosuppressive therapy is discontinued when immune competence is restored.(2)

DISCUSSION: Vaccinations may be less effective if administered during and for up to 3 months after ozanimod treatment.(1) However they are considered safe to administer.

Non-Live Or Non-Replicating Vaccines/Ponesimod

SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed.

MECHANISM OF ACTION: Ponesimod is an immunosuppressant and may alter the immune system's response to vaccines.(1)

CLINICAL EFFECTS: Administration of a vaccine during and for up to 2 weeks after discontinuation of ponesimod therapy may result in decreased effectiveness of the vaccine. Ponesimod treatment should be paused 1-2 weeks prior and for 4 weeks after vaccination.(1)

PREDISPOSING FACTORS: None determined.

PATIENT MANAGEMENT: Ideally, administer vaccines prior to initiating ponesimod therapy. The immune response to non-live vaccines should be monitored in patients receiving ponesimod or who have received ponesimod in the previous 2 weeks. Vaccinations given during and for up to 2 weeks after discontinuation of ponesimod therapy may need to be repeated.(1) The Centers for Disease Control's (CDC) Advisory Committee on Immunization Practices (ACIP) states that non-live vaccines should be used with caution in patients who are severely immunosuppressed. Patients who are vaccinated within the 14 days prior to initiating immunosuppressive therapy should be considered unvaccinated and should be revaccinated at least 3 months after immunosuppressive therapy is discontinued when immune competence is restored.(2)

DISCUSSION: Vaccinations may be less effective if administered during and for up to 2 weeks after ponesimod treatment.(1) However they are considered safe to administer.

Non-Live Or Non-Replicating Vaccines/Satralizumab

SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed.

MECHANISM OF ACTION: Satralizumab is an immunosuppressant and may alter the immune system's response to vaccines.(1)

CLINICAL EFFECTS: Administration of a vaccine during satralizumab therapy may result in decreased effectiveness of the vaccine. If possible, non-live vaccines should be administered at least two weeks prior to initiation of satralizumab.(1)

PREDISPOSING FACTORS: None determined.

PATIENT MANAGEMENT: Ideally, administer vaccines two weeks prior to initiating satralizumab therapy. The immune response to non-live vaccines should be monitored in patients receiving satralizumab. Vaccinations given during satralizumab therapy may need to be repeated.(1) Patients who are vaccinated within the 14 days prior to initiating immunosuppressive therapy should be considered unvaccinated and should be revaccinated at least 3 months after immunosuppressive therapy is discontinued when immune competence is restored.(2)

DISCUSSION: Vaccinations may be less effective if administered during satralizumab treatment.(1)

Non-Live Or Non-Replicating Vaccines/Siponimod

SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed.

MECHANISM OF ACTION: Siponimod is an immunosuppressant and may alter the immune system's response to vaccines.(2)

CLINICAL EFFECTS: Administration of a vaccine during and for up to 1 month after discontinuation of siponimod therapy may result in decreased effectiveness of the vaccine. Siponimod treatment should be paused 1 week prior and for 4 weeks after vaccination.(2)

PREDISPOSING FACTORS: None determined.

PATIENT MANAGEMENT: Ideally, administer vaccines prior to initiating siponimod therapy. The immune response to non-live vaccines should be monitored in patients receiving siponimod or who have received siponimod in the previous week. Vaccinations given during and for up to 1 month after discontinuation of siponimod therapy may need to be repeated.(2) The Centers for Disease Control's (CDC) Advisory Committee on Immunization Practices (ACIP) states that non-live vaccines should be used with caution in patients who are severely immunosuppressed. Patients who are vaccinated within the 14 days prior to initiating immunosuppressive therapy should be considered unvaccinated and should be revaccinated at least 3 months after immunosuppressive therapy is discontinued when immune competence is restored.(3)

DISCUSSION: Vaccinations may be less effective if administered during and for up to 1 month after siponimod treatment(2) however they are considered safe to administer.(1)

Non-Live Or Non-Replicating Vaccines/Ublituximab

SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed.

MECHANISM OF ACTION: Ublituximab is an immunosuppressant and may alter the immune system's response to vaccines.(1)

CLINICAL EFFECTS: Administration of a non-live vaccine within 2 weeks before or during ublituximab therapy may result in decreased effectiveness of the vaccine. If possible, non-live vaccines should be administered at least two weeks prior to initiating ublituximab therapy.(1)

PREDISPOSING FACTORS: None determined.

PATIENT MANAGEMENT: Ideally, administer non-live vaccines at least two weeks prior to initiating ublituximab therapy. The immune response to non-live vaccines should be monitored in patients receiving ublituximab. Vaccinations given during ublituximab therapy may need to be repeated.(1) Patients who are vaccinated within the 14 days prior to initiating immunosuppressive therapy should be considered unvaccinated and should be revaccinated at least 3 months after immunosuppressive therapy is discontinued when immune competence is restored.(2)

DISCUSSION: Vaccinations may be less effective if administered within 2 weeks before or during ublituximab treatment.(1)

Non-Live Or Nonreplicating Vaccine/Vusolimogene Oderparepvec

SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed.

MECHANISM OF ACTION: The interaction potential of non-live or non-replicating vaccines with vusolimogene oderparepvec is unknown.

CLINICAL EFFECTS: Concurrent administration of non-live or non-replicating vaccines with vusolimogene oderparepvec may alter the effectiveness or toxicities of either agent.

PREDISPOSING FACTORS: None determined.

PATIENT MANAGEMENT: The manufacturer of vusolimogene oderparepvec states that non-live and non-replicating vaccines should ideally be delayed until the current course of vusolimogene oderparepvec therapy is completed. If vaccination is required during treatment, separate administration of the vaccine and vusolimogene oderparepvec by at least 14 days.(2) Patients should be advised that their cancer gene therapy may be delayed due to administration of vaccines.(3)

DISCUSSION: The concomitant use of non-live or non-replicating vaccines and vusolimogene oderparepvec has not been evaluated. The manufacturer's recommendation is intended to minimize potential interactions and confounding factors in the safety assessments of vaccines and vusolimogene oderparepvec therapy.(2)

Vaccines/Hepatitis B Vaccine (Fendrix)

SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed.

MECHANISM OF ACTION: No data is available on the concurrent administration of the hepatitis B vaccine Fendrix and other vaccines.(1)

CLINICAL EFFECTS: It is unknown if concurrent administration of the hepatitis B vaccine Fendrix and other vaccines will affect the efficacy of either vaccine.(1)

PREDISPOSING FACTORS: None determined.

PATIENT MANAGEMENT: The Swedish manufacturer of Fendrix states that since there is no data available for the concurrent administration of Fendrix with other vaccines, the administration of Fendrix and other vaccines should be separated by 2 to 3 weeks.(1)

DISCUSSION: No data is available on the concurrent administration of the hepatitis B vaccine Fendrix with other vaccines.(1)

*Severe allergic reactions (e.g., anaphylaxis) after previous dose of DTaP, any vaccine component, or any vaccine containing tetanus, diphtheria, or pertussis antigens.

*Encephalopathy (e.g., coma, decreased level of consciousness, prolonged seizures) within 7 days of a previous dose of a vaccine containing pertussis antigens that is not attributable to another identifiable cause.

*Progressive neurologic disorder, including infantile spasms, uncontrolled epilepsy, or progressive encephalopathy (DTaP only).

There are no contraindication contraindications for this drug.

• Coma
• Guillain-barre syndrome
• Uncontrolled epilepsy

There are no moderate contraindications for this drug.

Rates of adverse effects following DTaP (Daptacel(R), Infanrix(R)) administration varied by dose number, with injection site reactions (pain, redness, swelling) the most frequent following doses 4 and 5. Common systemic adverse effects with DTaP vaccination include fever, drowsiness, fussiness/irritability, inconsolable crying, loss of appetite, and lethargy.

Following the first booster dose of Tdap (Adacel(R)), the most common adverse effects within the first 2 weeks of vaccination for adolescents were injection site pain (77.8%), headache (43.7%), body aches or muscle weakness (30.4%), tiredness (30.2%), injection site swelling (20.9%), and injection site redness (20.8%). In adults 18-64 years of age, the most common adverse effects within the first 2 weeks were injection site pain (65.7%), headache (33.9%), body aches or muscle weakness (21.9%), tiredness (24.3%), injection site swelling (21%), and injection site redness (24.7%). Within the first week after a second booster dose of Tdap (Adacel(R)), the most common adverse effects in patients 18-64 years of age were injection site pain (87.1%), myalgia (58.1%), headache (41.4%), malaise (33.3%), injection site swelling (6.9%), and injection site erythema (6.4%).

Adverse effects reported in >=15% of adolescents and adults 10-64 years of age following administration of Tdap (Boostrix(R)) were injection site reactions (pain, redness, swelling), headache, fatigue, and GI symptoms. Increased arm circumference was also reported in adolescent patients. In adults >=65 years of age, the most common adverse effect was pain at the injection site.

Rare or Very Rare

• Anaphylaxis
• Angioedema
• Apnea
• Brachial plexus disorder
• Cyanosis
• Encephalitis
• Encephalopathy
• Extensive limb swelling after injection
• Guillain-barre syndrome
• High fever >101 degrees fahrenheit
• Hypersensitivity drug reaction
• Hypotension
• IgA vasculitis
• Myelitis
• Myocarditis
• Myositis
• Seizure disorder
• Syncope
• Thrombocytopenic disorder
• Tonic clonic seizure
• Unconsciousness
• Urticaria

More Frequent

• Anorexia
• Fatigue
• Headache disorder
• Injection site sequelae
• Myalgia

Less Frequent

• Acute abdominal pain
• Arthralgia
• Chills
• Diarrhea
• Lymphadenopathy
• Nausea
• Skin rash
• Vomiting

Rare or Very Rare

• Back pain
• Bronchitis
• Bruising
• Cellulitis
• Cough
• Drowsy
• Earache
• Edema
• Erythema
• Facial palsy
• Fever
• Hypoesthesia
• Induration of skin
• Injection site abscess
• Muscle spasm
• Paresthesia
• Pruritus of skin
• Upper respiratory infection

No enhanced messaging available.

Safety and efficacy of DTaP (Daptacel(R), Infanrix(R)) in children younger than 6 weeks of age or in children 7 years of age or older have not been established.

Safety and efficacy of Tdap (Adacel(R), Boostrix(R)) in children <10 years of age have not been established.

Tdap (Adacel(R), Boostrix(R)) is indicated for immunization during the third trimester of each pregnancy to prevent pertussis in infants <2 months of age.

Available data indicate that rates of major birth defects and miscarriage are similar in women who received Adacel(R) or Boostrix(R) 28-30 days prior to pregnancy and during pregnancy compared to background estimated rates.

A retrospective passive surveillance study compared outcomes between 225 women who received Adacel(R) during pregnancy and 675 controls matched by age and date of their first positive pregnancy test. Of the Adacel(R) recipients, 110 were vaccinated in the first trimester, 33 during the second trimester, and 14 in the third trimester. Twenty-nine had an unknown time of vaccination, and 39 had received Adacel(R) within 2 weeks prior to their last menstrual period. Spontaneous abortions were reported in 15% of patients in the control group and 9.3% of Adacel(R) recipients. The incidence of congenital anomalies was 8.4% in the control group and 6.7% in the group exposed to Adacel(R).

An assessment of 1236 prospective reports from an ongoing registry of exposure to Adacel(R) indicate that rates of assessed outcomes (e.g., congenital anomalies, spontaneous abortions) in the prospective population were consistent with estimated background rates.

Among 256 reports with known pregnancy outcomes in women exposed to Boostrix(R) within 28 days prior to conception or during pregnancy, 19 women with first trimester exposure to Boostrix(R) had no reported major birth defects and 3 spontaneous abortions. Twenty-eight women exposed in the second trimester and 199 in the third trimester also reported no major birth defects; an additional 10 women that were exposed to Boostrix(R) at an unknown timing during pregnancy reported no major birth defects.

Other spontaneous reports and postmarketing data have shown that out of 138 reports with known pregnancy outcomes, there were no major birth defects and 2 spontaneous abortions among 17 women exposed to Boostrix(R) in the first trimester. Out of 26 exposures in the second trimester and 92 in the third trimester there were no major birth defects reported; 3 women exposed to Boostrix(R) at an unknown timing during pregnancy also had no major birth defects reported.

Irrespective of vaccine history, ACIP and ACOG recommend administering a single dose of Tdap (Adacel(R) or Boostrix(R)) in all pregnant women during each pregnancy as early as possible between 27 and 36 weeks gestation. Immunization with Tdap during the third trimester of pregnancy provides passive protection against pertussis via transplacental antibody transfer in infants <2 months of age.

Clinicians are encouraged to register pregnant women who receive Tdap with the manufacturer's pregnancy registry at 800-822-2463 or https://www.sanofipasteurpregnancyregistry.com (Adacel(R)) or 888-452-9622 or https://pregnancyregistry.gsk.com/boostrix.html (Boostrix(R)).

It is not known whether Tdap (Adacel(R), Boostrix(R)) is distributed into human milk and data on the effect on breast-fed infants or on milk production are not available. The manufacturers state that Tdap should be used with caution in breast-feeding women.

Manufacturers do not provide specific dosage recommendations for geriatric patients.

Clinical studies evaluating the safety and efficacy of Tdap (Boostrix(R)) included adults >=65 years of age, and this preparation is labeled by FDA for booster immunization in geriatric adults.

Safety and efficacy of Tdap (Adacel(R)) have not been established in adults >=65 years of age. Although Tdap (Adacel(R)) is not labeled by FDA for use in adults >=65 years of age, ACIP states the vaccine can be used in this age group if it is the only Tdap vaccine available.